Meeting
2017 ASCO Annual Meeting
Phase II trial of neoadjuvant (neo) palbociclib (Palbo) plus anastrozole (ana) in endocrine resistant clinical stage 2/3 estrogen receptor positive and HER2 negative (ER+ HER2-) breast cancer (BC).
Authors
Nusayba Ali Bagegni
Washington University School of Medicine in St. Louis, St. Louis, MO
Nusayba Ali Bagegni , Feng Gao , Matthew P. Goetz , Donald W. Northfelt , Andres Forero-Torres , Jill Anderson , Kiran R. Vij , Souzan Sanati , Matthew J Ellis , Cynthia X. Ma
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
NCT01723774
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS592)
DOI
10.1200/JCO.2017.35.15_suppl.TPS592
Abstract #
TPS592
Poster Bd #
189a
Abstract Disclosures
Similar Posters
First Author: Yeon Hee Park
Poster
2021 ASCO Annual Meeting
Impact of endocrine therapy on overall survival in ER negative/PR positive locoregional breast cancer: An analysis of the National Cancer Database.
First Author: Vidya Kollu
Poster
2020 ASCO Virtual Scientific Program
A phase II trial of nivolumab (NIVO) + palbociclib (PAL) + anastrozole (ANA) in postmenopausal women and men with estrogen receptor (ER)+/human epidermal growth factor 2 (HER2)- primary breast cancer (BC): CheckMate 7A8.
First Author: Sara M. Tolaney
Poster
2018 ASCO Annual Meeting
Selection for Oncotype Dx testing among young women with early-stage ER+/HER2- breast cancer.
First Author: Philip Daniel Poorvu